<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01634412</url>
  </required_header>
  <id_info>
    <org_study_id>TNX-CY-F102</org_study_id>
    <nct_id>NCT01634412</nct_id>
  </id_info>
  <brief_title>Comparative Bioavailability of Sublingual TNX-102, Oral and Intravenous Cyclobenzaprine in Healthy Adults</brief_title>
  <official_title>A Single-Dose, Open-Label, Randomized Study of the Comparative Pharmacokinetics of Sublingual TNX-102 2.4 mg at pH 3.5 and 7.1, Oral Cyclobenzaprine 5 mg Tablets, and Intravenous Cyclobenzaprine 2.4 mg in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tonix Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tonix Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Very low dose (VLD) cyclobenzaprine at bedtime has shown promise as a treatment for
      fibromyalgia, but the chemistry of cyclobenzaprine requires new formulation technology for
      bedtime use. The present trial is designed to assess the safety and tolerability of
      sublingual TNX-102 2.4 mg (a new formulation of cyclobenzaprine designed to result in
      increased dosage precision and decreased potential for morning grogginess) at pH 3.5 and 7.1
      and to compare the bio-availability of sublingual TNX-102 2.4 mg at pH 3.5 and 7.1 and
      cyclobenzaprine (5 mg tablets, or 2.4 mg iv).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>â€¢ Measured levels of cyclobenzaprine and norcyclobenzaprine in plasma and urine</measure>
    <time_frame>27 time points per period for blood assessment ; 3 pooled analyses in urine.</time_frame>
    <description>Blood samples will be taken per period: within 30 minutes pre-dose and 2, 3.5, 5, 10, 20, 30, and 45 minutes and 1, 2, 2.5, 3, 3.33, 3.67, 4, 4.33, 4.67, 5, 5.5, 6, 8, 12, 16, 24, 36, 48, and 72 hours post-dose. A single urine sample will be collected within 30 minutes pre-dose (one sample), and urine will be pooled from 0-24, 24-48 and 48-72 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of sublingual TNX-102 2.4 mg at pH 3.5 and pH 7.1.</measure>
    <time_frame>Continuously until the end (day 4) of the study period + Telephone follow-up 7-13 days after dosing (total duration: about 1 month)</time_frame>
    <description>Every adverse events occurring during the study period will be reported.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>SL TNX-102 at pH 3.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SL TNX-102 at pH 7.1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclobenzaprine tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg cyclobenzaprine tablet once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclobenzaprine IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SL TNX-102 2.4 mg at pH 3.5</intervention_name>
    <description>1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5, administered as 1 mL held under the tongue for 90 seconds without swallowing</description>
    <arm_group_label>SL TNX-102 at pH 3.5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SL TNX-102 2.4 mg at pH 7.1</intervention_name>
    <description>1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1, administered as 1 mL held under the tongue for 90 seconds without swallowing</description>
    <arm_group_label>SL TNX-102 at pH 7.1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclobenzaprine Tablet</intervention_name>
    <description>1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water</description>
    <arm_group_label>Cyclobenzaprine tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclobenzaprine IV</intervention_name>
    <description>1 dose of 2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4, administered intravenously as a 4 mL bolus injection over 30 seconds</description>
    <arm_group_label>Cyclobenzaprine IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Healthy adults

          -  Male or female

          -  Non-smoker

          -  18-65 years old

          -  BMI &gt; 18.5 and &lt; 30.0

          -  With medically acceptable form of contraception (female only)

          -  With signed informed consent

        Exclusion Criteria:

          -  Any clinically significant abnormality including ECG abnormalities or vital sign
             abnormalities (systolic blood pressure &lt; 90 or &gt; 140 mmHg, diastolic blood pressure
             lower &lt; 50 or &gt; 90 mmHg, or heart rate &lt; 50 or &gt; 100 BPM)

          -  Any abnormal laboratory test (including positivity for Hep B, Hep C, HIV, and
             Hemoglobin &lt; 128 g/L (males) or &lt; 115 g/L (females) and hematocrit &lt; 0.37 L/L (males)
             or &lt; 0.32 L/L (females))

          -  History of alcohol or drug abuse or dependence within 1 year and/or positive drug,
             cotinine, or alcohol tests

          -  Use of any drug (within 30 days), supplement, or food (within 14 days) known to induce
             or inhibit hepatic drug metabolism prior to study medication

          -  Positive pregnancy test, breastfeeding or lactating

          -  Use of medication other than hormonal contraceptives or topical products, including
             OTC, natural health products, MAO inhibitors

          -  Participation in an investigational study within 30 days prior to dosing

          -  Donation of plasma (within 7 days), or donation or loss of blood of 50-499 mL
             (within30 days), or of &gt; 499 mL (within 56 days) prior to dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seth M. Lederman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tonix Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey P. Kitrelle, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tonix Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Denis Audet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PharmaNet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PharmaNet, Inc.</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1P 0A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2012</study_first_submitted>
  <study_first_submitted_qc>July 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2012</study_first_posted>
  <last_update_submitted>September 24, 2014</last_update_submitted>
  <last_update_submitted_qc>September 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Cyclobenzaprine</mesh_term>
    <mesh_term>Amitriptyline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

